Actelion Pharmaceuticals US, Inc. drugs
6 results
Opsumit (macitentan)
(macitentan)Actelion Pharmaceuticals US, Inc.
Usage: OPSUMIT is indicated for the treatment of pulmonary arterial hypertension (PAH) in adults, aiming to reduce disease progression and hospitalization risks. Its effectiveness was demonstrated in a long-term study involving patients with various types of PAH, primarily those with WHO Functional Class II–III symptoms.
Tracleer (bosentan)
(bosentan)Actelion Pharmaceuticals US, Inc.
Usage: TRACLEER is indicated for the treatment of pulmonary arterial hypertension (PAH) in adults to improve exercise ability and decrease clinical worsening. It is also approved for pediatric patients aged 3 and older with idiopathic or congenital PAH to improve pulmonary vascular resistance and exercise ability.
Uptravi (selexipag)
(Selexipag)Actelion Pharmaceuticals US, Inc.
Usage: UPTRAVI is indicated for treating pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce hospitalization risk. Its effectiveness is supported by a long-term study involving patients with WHO Functional Class II–III symptoms and various PAH causes.
Veletri (epoprostenol)
(epoprostenol)Actelion Pharmaceuticals US, Inc.
Usage: VELETRI is indicated for treating pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity, primarily in patients with NYHA Functional Class III–IV symptoms, including those with idiopathic, heritable PAH, or PAH related to connective tissue diseases.
Ventavis (iloprost)
(iloprost)Actelion Pharmaceuticals US, Inc.
Usage: VENTAVIS is indicated for treating pulmonary arterial hypertension (PAH) to enhance exercise tolerance, alleviate symptoms, and prevent deterioration. It is primarily studied in patients with NYHA Functional Class III–IV PAH, including idiopathic, heritable, and connective tissue disease-associated types.
Zavesca (miglustat)
(miglustat)Actelion Pharmaceuticals US, Inc.
Usage: ZAVESCA is indicated as a standalone treatment for adult patients with mild to moderate type 1 Gaucher disease when enzyme replacement therapy is not viable due to factors like allergy, hypersensitivity, or inadequate venous access.